Weekly Antepartum Testing in Women With BMI 30-40 and Neonatal Outcomes
NCT ID: NCT04180566
Last Updated: 2021-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2020-02-04
2021-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perinatal Outcomes in Nutritionally Monitored Obese Pregnant Women
NCT00740766
Newborns of Obese Mothers
NCT02681588
Antenatal Testing in Obese Woman, is it Really Necessary?
NCT02821988
New Biomarkers Associated With the Risk of Premature Delivery.
NCT04067908
Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child
NCT03084120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Weekly antenatal testing
Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
Antenatal Testing (biophysical profile)
Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
Growth ultrasound examination every 4 weeks
Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.
Ultrasound Examination
Includes a regular growth ultrasound examination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound Examination
Includes a regular growth ultrasound examination.
Antenatal Testing (biophysical profile)
Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton pregnancy with no major fetal anomalies
* Pregnancies and gestational age will be well dated
* Obese with BMI 30-40kg/m2
Exclusion Criteria
* Women with indication for weekly testing as per local protocol
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cynthia Gyamfi-Bannerman, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
Professor of Obstetrics/Gyn, Columbia University
Maria Andrikopoulou, MD, PhD
Role: STUDY_CHAIR
Postdoctoral Clinical Fellow in the Department of Obstetrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia Univeristy Irving Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAS5275
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.